• linkedin
  • Increase Font
  • Sharebar

    A promising target for immunotherapy?


    An ultra-fast system combining xenografts derived from primary tumors and metastases in patients with renal cell carcinoma combined with multiregional genomic sequencing provided a readout of drug resistance based on phenotype and holds promise for guiding personalized drug selection.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available